EIKN
Eikon Therapeutics, Inc. Common StockNASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage limited
$6.72-7.44%
Close Oct 13, 2026
- Market cap
- $363.88M
- 1 month
- -28.2%
- 3 months
- -31.7%
- 1 year
- —
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$1.58Quarter to Sep 30, 2026 · 4 analysts · revenue $0
- Short interest
- 21.2% of float6.3M shares · settled Sep 30, 2026 · +15.4% since Sep 15, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- —
- Net income
- -$322.16M
- Free cash flow
- -$259.2M
- Book value
- $466.5M
- Total debt
- $252.22M
- P/E
- —
- Price / sales
- —
- Price / book
- 0.8×
- FCF yield
- -71.2%
- Net margin
- —
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if EIKN is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
18 top institutions tracked
as of 2026-Q2 (filed 2026-09-22)
Last 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: neutral
Last trade: buy 37 days ago
Red flags: 0
Largest 13-F holders · Q2 2026
77 filers reported a long position in EIKN for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| FMR LLC | $65.2M | 5M | +30.2% |
| BlackRock, Inc. | $55.9M | 4.3M | +29% |
| Foresite Capital Management IV, LLC | $25.4M | 1.9M | Unchanged |
| Merck & Co., Inc. | $21.7M | 1.7M | Unchanged |
| T. Rowe Price Investment Management, Inc. | $20.8M | 1.6M | +30.5% |
| Foresite Capital Management V, LLC | $17.2M | 1.3M | Unchanged |
| Capital World Investors | $15.3M | 1.2M | +2.8% |
| PRICE T ROWE ASSOCIATES INC /MD/ | $13.1M | 1M | +3% |
| VANGUARD CAPITAL MANAGEMENT LLC | $12M | 922.7K | -4.8% |
| EcoR1 Capital, LLC | $9.6M | 732.6K | Unchanged |
Get the Full Analysis for EIKN
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.